{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T02:05:39Z","timestamp":1769047539056,"version":"3.49.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA270085"],"award-info":[{"award-number":["K08CA270085"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005601","name":"CLL Global Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.hoc.2025.05.011","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T15:44:15Z","timestamp":1751903055000},"page":"997-1012","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Advances in the Understanding of Richter Transformation"],"prefix":"10.1016","volume":"39","author":[{"given":"Philip A.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin M.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.hoc.2025.05.011_bib1","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","article-title":"Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior","volume":"95","author":"Gine","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.011_bib2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/his.13024","article-title":"Diagnostic dilemmas of high-grade transformation (Richter\u2019s syndrome) of chronic lymphocytic leukaemia: results of the phase II National Cancer Research Institute CHOP-OR clinical trial specialist haemato-pathology central review","volume":"69","author":"Soilleux","year":"2016","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.011_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world Health Organization Classification of Haematolymphoid tumours: lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib4","first-page":"e22","article-title":"Pseudo-Richter transformation of chronic lymphocytic leukaemia\/small lymphocytic lymphoma following ibrutinib interruption: a diagnostic pitfall","volume":"191","author":"Barnea","year":"2020","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.011_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International consensus Classification of mature lymphoid Neoplasms: a report from the clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.011_bib6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1634\/theoncologist.2020-0388","article-title":"Disease flare during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia","volume":"25","author":"Hampel","year":"2020","journal-title":"Oncologist"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.011_bib7","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.011_bib8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.canep.2019.04.002","article-title":"Richter syndrome epidemiology in a large population based chronic lymphocytic leukemia cohort from Norway","volume":"60","author":"Lenartova","year":"2019","journal-title":"Cancer Epidemiol"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.011_bib9","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1182\/blood.V94.2.448","article-title":"Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases","volume":"94","author":"Mauro","year":"1999","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.011_bib10","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/bjh.12458","article-title":"Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients","volume":"162","author":"Parikh","year":"2013","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.hoc.2025.05.011_bib11","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1200\/JCO.2005.05.0187","article-title":"Clinical outcomes and prognostic factors in patients with Richter\u2019s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation","volume":"24","author":"Tsimberidou","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"issue":"31","key":"10.1016\/j.hoc.2025.05.011_bib13","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.011_bib14","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.011_bib15","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41375-024-02492-4","article-title":"Incidence of Richter transformation of chronic lymphocytic leukemia\/small lymphocytic lymphoma in the targeted therapy era","volume":"39","author":"Hampel","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.011_bib16","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2007.06801.x","article-title":"Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia","volume":"139","author":"Maddocks-Christianson","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/ajh.26755","article-title":"Patient characteristics that predict Richter\u2019s transformation in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"98","author":"Kittai","year":"2023","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.011_bib18","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/bloodadvances.2017007302","article-title":"Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib","volume":"1","author":"Miller","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41591-022-02113-6","article-title":"Evolutionary history of transformation from chronic lymphocytic leukemia to Richter syndrome","volume":"29","author":"Parry","year":"2023","journal-title":"Nat Med"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.011_bib20","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-08-3266","article-title":"Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome","volume":"15","author":"Rossi","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.hoc.2025.05.011_bib21","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.011_bib22","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.011_bib23","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.011_bib24","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/2159-8290.CD-21-0276","article-title":"Longitudinal single-cell dynamics of chromatin accessibility and mitochondrial mutations in chronic lymphocytic leukemia mirror disease history","volume":"11","author":"Penter","year":"2021","journal-title":"Cancer Discov"},{"issue":"15","key":"10.1016\/j.hoc.2025.05.011_bib25","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.011_bib26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41375-023-02095-5","article-title":"Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter transformation","volume":"38","author":"Playa-Albinyana","year":"2024","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41467-022-34642-6","article-title":"Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis","volume":"14","author":"Broseus","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib28","first-page":"11","article-title":"Richter syndrome: novel insights into the biology of transformation","volume":"142","author":"Parry","year":"2023","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.011_bib29","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1097\/PAS.0b013e31804bdaf8","article-title":"IgVH mutational status and clonality analysis of Richter\u2019s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution","volume":"31","author":"Mao","year":"2007","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.011_bib30","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/bjh.16748","article-title":"Clinical outcome and prognostic factors of patients with Richter syndrome: real-world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC)","volume":"190","author":"Abrisqueta","year":"2020","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.011_bib31","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib32","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41408-025-01236-6","article-title":"Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL","volume":"15","author":"Kittai","year":"2025","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.011_bib33","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41375-021-01181-w","article-title":"BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma","volume":"35","author":"Fiskus","year":"2021","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.hoc.2025.05.011_bib34","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1158\/0008-5472.CAN-17-4004","article-title":"Novel richter syndrome xenograft models to study genetic architecture, biology, and therapy responses","volume":"78","author":"Vaisitti","year":"2018","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.011_bib35","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood.2020008276","article-title":"B-cell receptor signaling and genetic lesions in TP53 and CDKN2A\/CDKN2B cooperate in Richter transformation","volume":"138","author":"Chakraborty","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/s41467-022-35778-1","article-title":"Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter\u2019s transformation","volume":"14","author":"Hing","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41467-017-00210-6","article-title":"Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia","volume":"8","author":"Knittel","year":"2017","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.hoc.2025.05.011_bib38","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-19-0273","article-title":"Emu-TCL1xMyc: a novel mouse model for concurrent CLL and B-Cell Lymphoma","volume":"25","author":"Lucas","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.011_bib39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1158\/2643-3230.BCD-22-0082","article-title":"In vivo modeling of CLL transformation to richter syndrome reveals convergent evolutionary paths and therapeutic vulnerabilities","volume":"4","author":"Ten Hacken","year":"2023","journal-title":"Blood Cancer Discov"},{"issue":"758","key":"10.1016\/j.hoc.2025.05.011_bib40","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adg7915","article-title":"MGA deletion leads to Richter\u2019s transformation by modulating mitochondrial OXPHOS","volume":"16","author":"Iyer","year":"2024","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14756","article-title":"Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia","volume":"8","author":"Yeh","year":"2017","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.hoc.2025.05.011_bib42","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","article-title":"Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures","volume":"11","author":"Kotlov","year":"2021","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.011_bib43","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/s41556-024-01358-2","article-title":"Multimodal and spatially resolved profiling identifies distinct patterns of T cell infiltration in nodal B cell lymphoma entities","volume":"26","author":"Roider","year":"2024","journal-title":"Nat Cell Biol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.011_bib44","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41556-020-0532-x","article-title":"Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels","volume":"22","author":"Roider","year":"2020","journal-title":"Nat Cell Biol"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.011_bib45","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.hoc.2025.05.011_bib46","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood.2024025355","article-title":"Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response","volume":"145","author":"Tumuluru","year":"2025","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.011_bib47","doi-asserted-by":"crossref","first-page":"E239","DOI":"10.1002\/ajh.23841","article-title":"Poor efficacy and tolerability of R-CHOP in relapsed\/refractory chronic lymphocytic leukemia and Richter transformation","volume":"89","author":"Langerbeins","year":"2014","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2025.05.011_bib48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/10428190109064589","article-title":"Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter\u2019s syndrome","volume":"42","author":"Dabaja","year":"2001","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.011_bib49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/10428190290016872","article-title":"Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter\u2019s syndrome or refractory lymphoproliferative disorders","volume":"43","author":"Tsimberidou","year":"2002","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.011_bib50","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1200\/JCO.2007.11.8513","article-title":"Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter\u2019s syndrome or fludarabine-refractory chronic lymphocytic leukemia","volume":"26","author":"Tsimberidou","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.011_bib51","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.clml.2013.03.012","article-title":"Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed\/refractory chronic lymphocytic leukemia or richter syndrome","volume":"13","author":"Tsimberidou","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/hematology.2022000345","article-title":"Treatment of Richter\u2019s syndrome","volume":"2022","author":"Thompson","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"18","key":"10.1016\/j.hoc.2025.05.011_bib53","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.011_bib54","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1016\/S2352-3026(21)00305-7","article-title":"Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1-2 study","volume":"8","author":"Eyre","year":"2021","journal-title":"Lancet Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.011_bib55","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1182\/blood-2014-12-610782","article-title":"The efficacy of ibrutinib in the treatment of Richter syndrome","volume":"125","author":"Tsang","year":"2015","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.011_bib56","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000870","article-title":"Zanubrutinib, alone and in combination with tislelizumab, for the treatment of richter transformation of chronic lymphocytic leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Hemasphere"},{"issue":"9","key":"10.1016\/j.hoc.2025.05.011_bib57","doi-asserted-by":"crossref","first-page":"e682","DOI":"10.1016\/S2352-3026(24)00172-8","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1\/2 BRUIN study","volume":"11","author":"Wierda","year":"2024","journal-title":"The Lancet Haematology"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.011_bib58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1182\/blood-2021-147599","article-title":"Pirtobrutinib, a next generation, highly selective, non-covalent btk inhibitor in previously treated CLL\/SLL: updated Results from the Phase 1\/2 BRUIN Study","volume":"138","author":"Mato","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib59","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/hematology.2023000442","article-title":"Richter transformation-is there light at the end of this tunnel?","volume":"2023","author":"Eyre","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.011_bib60","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary efficacy and safety of the Bruton tyrosine Kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: results from the phase 1 CaDAnCe-101 study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.011_bib61","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/j.seminhematol.2024.01.015","article-title":"Therapeutic targeting of apoptosis in chronic lymphocytic leukemia","volume":"61","author":"Ahn","year":"2024","journal-title":"Semin Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2025.05.011_bib62","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.pathol.2022.12.354","article-title":"Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma","volume":"55","author":"El Hussein","year":"2023","journal-title":"Pathology"},{"issue":"8","key":"10.1016\/j.hoc.2025.05.011_bib63","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.011_bib64","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41419-024-06707-5","article-title":"Decreased apoptotic priming and loss of BCL-2 dependence are functional hallmarks of Richter\u2019s syndrome","volume":"15","author":"Rigo","year":"2024","journal-title":"Cell Death Dis"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.011_bib65","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood.2021011386","article-title":"Venetoclax plus dose-adjusted R-EPOCH for Richter syndrome","volume":"139","author":"Davids","year":"2022","journal-title":"Blood"},{"issue":"S2","key":"10.1016\/j.hoc.2025.05.011_bib66","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hon.3164_343","article-title":"Initial results of a multicenter phase 2 study of venetoclax in combination with R-CHOP (VR-CHOP) for patients with Richter Syndrome","volume":"41","author":"Davids","year":"2023","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.011_bib67","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/bloodadvances.2023012080","article-title":"A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia","volume":"8","author":"Hampel","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.011_bib68","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bjh.15514","article-title":"PD-1 is highly expressed by neoplastic B-cells in Richter transformation","volume":"185","author":"Behdad","year":"2019","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2025.05.011_bib69","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"A characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.011_bib70","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41408-021-00477-5","article-title":"Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.011_bib71","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1182\/blood-2017-02-765685","article-title":"Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL","volume":"129","author":"Ding","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.011_bib72","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/bjh.16762","article-title":"Pembrolizumab in relapsed or refractory Richter syndrome","volume":"190","author":"Armand","year":"2020","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.011_bib73","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.hoc.2025.05.011_bib74","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1016\/S2352-3026(18)30217-5","article-title":"Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1\/2a study","volume":"6","author":"Younes","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib75","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41591-023-02722-9","article-title":"Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial","volume":"30","author":"Al-Sawaf","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.hoc.2025.05.011_bib76","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1182\/blood-2021-154279","article-title":"Venetoclax, obinutuzumab and atezolizumab (PD-L1 Checkpoint Inhibitor) for treatment for patients with richter transformation","volume":"138","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.011_bib77","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.011_bib78","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/s41416-022-01743-4","article-title":"Biomarkers of response to PD-1 pathway blockade","volume":"126","author":"Li","year":"2022","journal-title":"British journal of cancer"},{"issue":"10","key":"10.1016\/j.hoc.2025.05.011_bib79","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.ccell.2023.08.013","article-title":"ZNF683 marks a CD8(+) T cell population associated with anti-tumor immunity following anti-PD-1 therapy for Richter syndrome","volume":"41","author":"Parry","year":"2023","journal-title":"Cancer Cell"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.011_bib80","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.hoc.2025.05.011_bib81","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large b-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2025.05.011_bib82","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-Cell-engaging antibody, in relapsed or refractory large B-Cell lymphoma: dose expansion in a phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.05.011_bib83","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"10402","key":"10.1016\/j.hoc.2025.05.011_bib84","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2025.05.011_bib85","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2020-138904","article-title":"Safety and efficacy of CD19-CAR T cells in Richter\u2019s transformation after targeted therapy for chronic lymphocytic leukemia","volume":"136","author":"Benjamini","year":"2020","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.hoc.2025.05.011_bib86","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1200\/JCO.24.00033","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for richter transformation: an International, multicenter, retrospective study","volume":"42","author":"Kittai","year":"2024","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.hoc.2025.05.011_bib87","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1182\/bloodadvances.2022007317","article-title":"Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia","volume":"6","author":"Gill","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.011_bib88","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2024-200339","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2025.05.011_bib89","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.hoc.2025.05.011_bib90","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.hoc.2025.05.011_bib91","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2025.05.011_bib92","first-page":"3566","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in de novo large B-cell lymphoma and transformed low-grade B-cell lymphoma","volume":"109","author":"Benjamini","year":"2024","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.05.011_bib93","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2023-173796","article-title":"Mosunetuzumab monotherapy demonstrates activity and a manageable safety profile in patients with relapsed or refractory Richter\u2019s transformation","volume":"142","author":"Cheah","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2025.05.011_bib94","doi-asserted-by":"crossref","unstructured":"Arnon P. Kater AJ, Herbert Eradat, Fritz Offner, Jose Sandoval-Sus, Mazyar Shadman, Christian Bj\u00f8rn Poulsen, Jacob Haaber Christensen, Meghan Thompson, Marcia Rios, Alexandra Kuznetsova, Toshiko Oki, Rebecca Valentin, Mar Bellido, Barbara Eichhorst. Single-agent epcoritamab leads to deep responses in patients (PTS) With Richter\u2019s Transformation (RT): primary results from the epcore CLL-1 trial. EHA2024.","DOI":"10.1016\/S2152-2650(24)00580-9"},{"issue":"S2","key":"10.1016\/j.hoc.2025.05.011_bib95","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hon.3163_28","article-title":"Glofitamab monotherapy induces durable complete remissions and has a manageable safety profile in patients with Richter\u2019s transformation","volume":"41","author":"Carlo-Stella","year":"2023","journal-title":"Hematol Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825000838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:50:27Z","timestamp":1760503827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825000838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":95,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0889858825000838"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.011","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the Understanding of Richter Transformation","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}